Sangamo Therapeutics

Biotech

Sangamo Therapeutics Inks $1.95B Deal With Genentech to Target Alzheimer’s, SGMO Stock Pops 29%

In a significant advancement for the field of genomic medicine, Sangamo Therapeutics has entered a landmark license agreement with Genentech,…

Read More »
Back to top button